Regulatory Resilience When Progress Pauses
The past few weeks have shown how much medtech depends on government systems running as planned. A shutdown slows communication with the FDA, delays grant award cycles, and pauses research. Timelines will shift, budgets must stretch, and teams need to adjust to uncertainty.
These challenges also affect the people inside those systems. The FDA carries significant responsibility. Its reviewers are scientists and public servants managing two priorities at once: protecting patients from harm and supporting innovation that improves care. When reviews take longer than expected, industry gripes about the pace. When products in the market fail, the agency carries the blame. During a shutdown, those pressures multiply, as workloads stay the same while resources shrink.
Through all of this, there are people doing good work to help all the different stakeholders make the best of a tough situation. Heath Naquin at University City Science Center is sharing practical tools and guidance to help startups do the “shutdown math” and map out contingency plans for regulatory delays. Kwame Ulmer at MedTech Impact Partners is encouraging companies that submitted before the shutdown to stay engaged through proactive communication and daily monitoring of the CDRH Portal. Allison Komiyama, PhD, RAC at Bluestocking Health, LLC, is connecting the efforts of innovators and regulators with the patients they serve, showing how clear communication supports safety and progress.
From the founder’s perspective, resilience starts with steadiness. Leading through unexpected slowdowns takes discipline. Teams still need direction, and investors still expect transparency, even when things stall. Regular check-ins and clear goals keep everyone aligned. Celebrating small wins keeps morale up. Downtime can become prep time; an opportunity to tighten documentation, run mock audits, and make sure traceability holds from design inputs through verification. Reviewing and strengthening design history files now builds confidence later, both with regulators and investors, while encouraging discipline and contingency planning across the team.
Resilience in this field comes from planning and follow-through. Keep your systems up to date, your data ready, and your team informed. Use downtime to tighten quality controls, review documentation, and prepare the next submission so you can move fast when the doors open again.
